{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:48:29Z","timestamp":1794300509696,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41397-019-0081-5","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:02:57Z","timestamp":1549411377000},"page":"564-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"19","author":[{"given":"Idoia","family":"Martin-Guerrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Gutierrez-Camino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizpea","family":"Echebarria-Barona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Astigarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagore","family":"Garcia de Andoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Navajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5575-3080","authenticated-orcid":false,"given":"Africa","family":"Garcia-Orad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"81_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166\u201378.","journal-title":"N Engl J Med"},{"key":"81_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/17425255.2014.885016","volume":"10","author":"R Said","year":"2014","unstructured":"Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol. 2014;10:483\u201394.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"81_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","volume":"596","author":"VA Carozzi","year":"2015","unstructured":"Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90\u2013107.","journal-title":"Neurosci Lett"},{"key":"81_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/pgs.14.68","volume":"15","author":"F Ceppi","year":"2014","unstructured":"Ceppi F, Langlois-Pelletier C, Gagn\u00e9 V, Rousseau J, Ciolino C, De LS, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15:1105\u201316.","journal-title":"Pharmacogenomics"},{"key":"81_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253\u201365.","journal-title":"Nat Rev Cancer"},{"key":"81_CR6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1046\/j.1365-2141.2000.t01-1-02153.x","volume":"110","author":"EJ Estlin","year":"2000","unstructured":"Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110:780\u201390.","journal-title":"Br J Haematol"},{"key":"81_CR7","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1021\/bi953037i","volume":"35","author":"S Lobert","year":"1996","unstructured":"Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry. 1996;35:6806\u201314.","journal-title":"Biochemistry"},{"key":"81_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815\u201323.","journal-title":"JAMA"},{"key":"81_CR9","doi-asserted-by":"crossref","unstructured":"Stock W, Diouf B, Crews KR, Pei D, Cheng D, Laumann K, et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2016;101:391\u201395.","DOI":"10.1002\/cpt.506"},{"key":"81_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","volume":"26","author":"A Gutierrez-Camino","year":"2016","unstructured":"Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, Echebarria-Barona A, Zabalza I, Ruiz I, et al. Lack of association of the CEP72rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharm Genom. 2016;26:100\u20132.","journal-title":"Pharm Genom"},{"key":"81_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/FPC.0000000000000192","volume":"26","author":"B Diouf","year":"2016","unstructured":"Diouf B, Crews KR, Evans WE. Vincristine pharmacogenomics: \u2018winner\u2019s curse\u2019 or a different phenotype? Pharm Genom. 2016;26:51\u201352.","journal-title":"Pharm Genom"},{"key":"81_CR12","doi-asserted-by":"publisher","first-page":"e91261","DOI":"10.1371\/journal.pone.0091261","volume":"9","author":"E L\u00f3pez-L\u00f3pez","year":"2014","unstructured":"L\u00f3pez-L\u00f3pez E, Guti\u00e9rrez-Camino \u00c1, Pi\u00f1\u00e1n M, Sanchez-Toledo J, Uriz JJ, Ballesteros J, et al. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS ONE. 2014;9:e91261.","journal-title":"PLoS ONE"},{"key":"81_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/FPC.0000000000000245","volume":"26","author":"L Iparraguirre","year":"2016","unstructured":"Iparraguirre L, Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Astigarraga I, Navajas A, et al. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharm Genom. 2016;26:517\u201325.","journal-title":"Pharm Genom"},{"key":"81_CR14","doi-asserted-by":"publisher","first-page":"D216","DOI":"10.1093\/nar\/gkr1026","volume":"40","author":"JD Ziebarth","year":"2012","unstructured":"Ziebarth JD, Bhattacharya A, Chen A, Cui Y. PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res. 2012;40:D216\u2013221.","journal-title":"Nucleic Acids Res"},{"key":"81_CR15","doi-asserted-by":"publisher","first-page":"D640","DOI":"10.1093\/nar\/gkp926","volume":"38","author":"S Hiard","year":"2010","unstructured":"Hiard S, Charlier C, Coppieters W, Georges M, Baurain D. Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res. 2010;38:D640\u2013651.","journal-title":"Nucleic Acids Res"},{"key":"81_CR16","doi-asserted-by":"publisher","first-page":"e30737","DOI":"10.1371\/journal.pone.0030737","volume":"7","author":"M Zorc","year":"2012","unstructured":"Zorc M, Skok DJ, Godnic I, Calin GA, Horvat S, Jiang Z, et al. Catalog of microRNA seed polymorphisms in vertebrates. PLoS ONE. 2012;7:e30737.","journal-title":"PLoS ONE"},{"key":"81_CR17","volume-title":"Molecular cloning: a laboratory manual","author":"J Sambrook","year":"2001","unstructured":"Sambrook J, Russell D. Molecular cloning: a laboratory manual. Third edition. New York: Cold Spring Harbor; 2001.","edition":"Third edition"},{"key":"81_CR18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, Ser B. 1995;57:289\u2013300.","journal-title":"J R Stat Soc, Ser B"},{"key":"81_CR19","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1126\/science.1069424","volume":"296","author":"SB Gabriel","year":"2002","unstructured":"Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225\u20139.","journal-title":"Science"},{"key":"81_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.leukres.2009.04.027","volume":"34","author":"A Hartman","year":"2010","unstructured":"Hartman A, van Schaik RH, van der Heiden IP, Broekhuis MJ, Meier M, Den Boer ML, et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk Res. 2010;34:154\u20139.","journal-title":"Leuk Res"},{"key":"81_CR21","doi-asserted-by":"publisher","first-page":"e0117511","DOI":"10.1371\/journal.pone.0117511","volume":"10","author":"M Okuda","year":"2015","unstructured":"Okuda M, Hijikuro I, Fujita Y, Wu X, Nakayama S, Sakata Y, et al. PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. PLoS ONE. 2015;10:e0117511.","journal-title":"PLoS ONE"},{"key":"81_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gr.129668.111","volume":"22","author":"LB Ramsey","year":"2012","unstructured":"Ramsey LB, Bruun GH, Yang W, Trevi\u00f1o LR, Vattathil S, Sheet P, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012;22:1\u20138.","journal-title":"Genome Res"},{"key":"81_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2217\/pgs-2016-0001","volume":"17","author":"E Lopez-Lopez","year":"2016","unstructured":"Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, Navajas A, Echebarria-Barona A, Garcia-Miguel P, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17:731\u201341.","journal-title":"Pharmacogenomics"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0081-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0081-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0081-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T15:25:41Z","timestamp":1720970741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0081-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["81"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0081-5","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"24 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}